Eculizumab

Paroxysmal Nocturnal Hemoglobinuria
Eculizumab is indicated for the treatment of adults and children with a condition affecting the blood system known as Paroxysmal Nocturnal Hemoglobinuria (PNH). In patients with PNH, red blood cells can be destroyed by the action of complement, leading to low red blood cell counts (anemia), fatigue, multi-organ dysfunction, chronic pain, dark urine, shortness of breath, and blood clots. Eculizumab can block the body’s inflammatory response and its ability to attack and destroy its own vulnerable blood cells (PNH cells). The clinical benefit of eculizumab has been demonstrated in the treatment of patients with hemolysis and clinical symptoms indicative of high disease activity, regardless of their transfusion history.